Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
167 pending office actions • 98 clients • 143 examiners • 64 art units • 0 of 167 (0%) have an AI response strategy ready
Clark+Elbing LLP has a substantial history in the Biotechnology & Pharmaceuticals technology area, having managed 8993 career applications. The firm has achieved a resolved allowance rate of 67.82 percent, reflecting the rigorous examination standards often encountered in life sciences prosecution. This allowance rate provides a realistic expectation for clients navigating the complexities of biotech patent law.
The firm averages 3.89 office actions per allowance, which offers a clear benchmark for the duration and intensity of the prosecution process. Currently, the firm is handling 129 pending office actions, maintaining a high level of active engagement relative to its 8993 career applications. These 129 pending office actions represent the firm's current responsive docket, which is informed by the extensive experience gained across its 8993 career applications. The average of 3.89 office actions per allowance highlights the persistent effort required to secure intellectual property in this field.
Based on the USPTO statutory response window for each pending office action. 50 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 50 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 19 (11%) |
| §103 only | 35 (21%) |
| §102 only | 4 (2%) |
| §112 only | 15 (9%) |
| Double-patenting only | 2 (1%) |
| Double-patenting + other | 21 (13%) |
| Multi-statute (no §101) | 69 (41%) |
| No statute on record | 1 (1%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, KHOA NHAT | 3 | 43.8% | +52.2% |
| NEAGU, IRINA | 3 | 46.8% | +57.3% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 3 | 33.3% | +38.9% |
| COFFA, SERGIO | 3 | 61.2% | +32.2% |
| REYNOLDS, FRED H | 3 | 33.0% | +39.2% |
| KAUFMAN, CLAIRE M | 3 | 63.3% | +50.7% |
| FAN, WEIHUA | 2 | 83.2% | +12.7% |
| PETTITT, JOHN F | 2 | 25.9% | +21.4% |
| LEE, ANDREW P | 2 | 48.3% | +23.1% |
| DAHLE, CHUN WU | 2 | 50.1% | +51.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709255 | BACTERIAL STRAINS FOR TREATING DISEASE | FAN, WEIHUA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17629918 | ADOPTIVE TRANSFER OF PLASMACYTOID DENDRITIC CELLS TO PREVENT OR TREAT HAIR LOSS | MIANO, JOSEPH PAUL | 134d overdue |
| 18024179 | METHODS FOR IDENTIFYING CROSS-MODAL FEATURES FROM SPATIALLY RESOLVED DATA SETS | TRAN, DUY ANH | 132d overdue |
| 18818268 | ANTIBODIES WITH FC MODIFICATIONS AND METHODS OF USING THE SAME | GUSTILO, ESTELLA M | 72d overdue |
| 18165613 | CELL MEMBRANE PENETRATING CONJUGATES | VARADARAJ, ARCHANA | 56d overdue |
| 17440081 | CARDIOMYOCYTE PROLIFERATION | TRAN, KHOA NHAT | 37d overdue |
| 18039812 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING MYOTONIC DYSTROPHY TYPE 1 | VIJAYARAGHAVAN, JAGAMYA NMN | 31d overdue |
| 17629313 | PEPTIDE HAVING HAIR GROWTH PROMOTING ACTIVITY, AND USE THEREOF | NIEBAUER, RONALD T | 3d overdue |
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | KONOPELSKI SNAVEL, SARA ELIZABETH | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17440081 | CARDIOMYOCYTE PROLIFERATION | TRAN, KHOA NHAT | 37d overdue |
| 17800639 | CXCL8 (INTERLEUKIN-8) ACTIVITY INHIBITOR AND CORTICOSTEROID COMBINATION AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LEE, ANDREW P | 19d overdue |
| 17748323 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN NEURAL PROGENITOR CELLS | TRAN, KHOA NHAT | 10d overdue |
| 17637392 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | COFFA, SERGIO | 3d overdue |
| 18024624 | PEPTIDES ENDOWED WITH ANGIOGENIC ACTIVITY | KONOPELSKI SNAVEL, SARA ELIZABETH | 5d |
| 18061755 | COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE | DAHLE, CHUN WU | 7d |
| 17413223 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS ACROSS THE ROUND WINDOW MEMBRANE | REYNOLDS, FRED H | 28d |
| 18140141 | METHODS OF TREATING LYMPHOPENIA | KAUFMAN, CLAIRE M | 60d |
| Art Unit | Apps |
|---|---|
| 1658 | 10 |
| 1632 | 9 |
| 1629 | 5 |
| 1631 | 5 |
| 1633 | 4 |
| 1654 | 4 |
| 1674 | 4 |
| 1684 | 4 |
| 1663 | 3 |
| 3991 | 3 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19388128 | DEVICES FOR KYPHOPLASTY AND METHODS OF USE THEREOF | Translational And Fundamental Technologies Institute LLC | GREEN, MICHELLE CHRISTINE | 3773 | §103 | Final Rejection | — | Pending | Nov 13, 2025 |
| 19162601 | MODIFIED NUCLEIC ACID SEQUENCE FOR CONFERRING CLUBROOT RESISTANCE TO CANOLA AND METHODS OF PRODUCING SAME | The Governors of the University of Alberta | FAN, WEIHUA | 1663 | §101§102§112 | Non-Final OA | — | Pending | Sep 05, 2025 |
| 19312085 | RECOMBINANT ADENOVIRUSES AND USE THEREOF | Washington University | DRISCOLL, LORA E BARNHART | 3991 | §101DP | Non-Final OA | — | Pending | Aug 27, 2025 |
| 19289942 | METHODS AND COMPOSITIONS FOR TREATING EPILEPSY | Uniqure France | QIAN, CELINE X | 1637 | §102DP | Non-Final OA | — | Pending | Aug 04, 2025 |
| 19265435 | COMPOUNDS AND METHODS FOR TREATING MUSCULAR DYSTROPHY AND OTHER DISORDERS | The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health | DIAMOND, ALAN D | 3991 | DP | Non-Final OA | — | Pending | Jul 10, 2025 |
| 19126720 | ELECTRONICALLY ENABLED PILL ORGANIZER | 9494-1861 Québec Inc. | MCCORMACK, THOMAS S | 2686 | §103 | Non-Final OA | — | Pending | May 02, 2025 |
| 19181929 | COMPOSITIONS AND METHODS FOR INDUCING OOCYTE MATURATION | Gameto, Inc. | CORDAS, EMILY ANN | 1632 | §102§103Other | Non-Final OA | — | Pending | Apr 17, 2025 |
| 19060439 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION OF HEPATOCYTES | Satellite Biosciences, Inc. | TRAN, KHOA NHAT | 1632 | §102§103 | Final Rejection | — | Pending | Feb 21, 2025 |
| 18876576 | COMPOSITIONS AND METHODS FOR THE PURIFICATION OF SQUALENE | Amyris, Inc. | FADHEL, ALI Z | §102§103 | Non-Final OA | — | Pending | Dec 18, 2024 | |
| 18980973 | MULTISENSOR BRACELET | Legionarius, LLC | HUNNINGS, TRAVIS R | 2689 | §102§103 | Non-Final OA | 22d | Pending | Dec 13, 2024 |
| 18853473 | ADENO-ASSOCIATED VIRUS POTENCY ASSAY AND USES THEREOF | Astellas Gene Therapies, Inc. | POPA, ILEANA | §103 | Non-Final OA | — | Pending | Oct 02, 2024 | |
| 18850703 | THERAPEUTIC USES OF BRADYKININ B2-RECEPTOR ANTAGONISTS | Pharvaris GmbH | ROZOF, TIMOTHY R | 1629 | §102§112DP | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18826883 | METHODS, COMPOSITIONS AND SYSTEMS FOR SOLID-STATE BAROCALORIC APPLICATIONS | President and Fellows of Harvard College | PETTITT, JOHN F | 3763 | §103§112 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18843373 | GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | Dompe' Farmaceutici Spa | REDWOOD, CHRISTOPHER EVAN | §103§112DP | Non-Final OA | — | Pending | Sep 03, 2024 | |
| 18821656 | METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA | Minerva Neurosciences, Inc. | RODRIGUEZ, RAYNA B | DP | Non-Final OA | — | Pending | Aug 30, 2024 | |
| 18818268 | ANTIBODIES WITH FC MODIFICATIONS AND METHODS OF USING THE SAME | The General Hospital Corporation | GUSTILO, ESTELLA M | 1646 | §103§112Other | Final Rejection | 72d overdue | Pending | Aug 28, 2024 |
| 18841472 | ORAL PCLX-001 IN THE TREATMENT OF HUMAN CANCER | Pacylex Pharmaceuticals Inc. | CORNET, JEAN P | §102§103§112 | Non-Final OA | — | Pending | Aug 26, 2024 | |
| 18838347 | NEURAL PROGENITOR CELL COMPOSITIONS AND METHODS OF USING THE SAME | The General Hospital Corporation | KASAYAN, KATRIEL BARCELLANO | §101§103§112 | Non-Final OA | — | Pending | Aug 14, 2024 | |
| 18572977 | DEXMECAMYLAMINE AND USES THEREOF | Atacama Therapeutics, Inc. | ROCHELLE, CIERRA MARIE | §103 | Non-Final OA | — | Pending | Aug 13, 2024 | |
| 18833242 | IMIDAZOPYRIDINE INHIBITORS OF TYROSINE KINASE | Bridgene Biosciences. Inc. | FETTEROLF, BRANDON J | §112 | Non-Final OA | — | Pending | Jul 25, 2024 | |
| 18769009 | RAS INHIBITORS | Revolution Medicines, Inc. | KIM, SEONG JONG | §112 | Non-Final OA | — | Pending | Jul 10, 2024 | |
| 18764714 | METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION | Minerva Neurosciences, Inc. | NEAGU, IRINA | §103§112 | Non-Final OA | — | Pending | Jul 05, 2024 | |
| 18724352 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | Caregen Co., Ltd. | KONOPELSKI SNAVEL, SARA ELIZABETH | §101§112 | Non-Final OA | — | Pending | Jun 26, 2024 | |
| 18724255 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | Caregen Co., Ltd. | COFFA, SERGIO | 1658 | §102§112 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18724295 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | Caregen Co., Ltd. | HA, JULIE | §101 | Non-Final OA | — | Pending | Jun 26, 2024 | |
| 18719260 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF | Alexion Pharmaceuticals, Inc. | ROMERO, KRISTEN WANG | §102§103Other | Non-Final OA | — | Pending | Jun 13, 2024 | |
| 18719261 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | Alexion Pharmaceuticals, Inc. | BAUER, BRIANNA LEE | §112 | Non-Final OA | — | Pending | Jun 13, 2024 | |
| 18714669 | METHOD OF GENERATING FUNCTIONAL ISLETS FROM PLURIPOTENT STEM CELLS | Hangzhou Reprogenix Bioscience, Inc. | MOSS, NATALIE M | §103§112 | Non-Final OA | — | Pending | May 30, 2024 | |
| 18709255 | BACTERIAL STRAINS FOR TREATING DISEASE | Microba Ip Pty Ltd. | FAN, WEIHUA | 1663 | §112 | Final Rejection | — | Pending | May 10, 2024 |
| 18659831 | PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF HBV | Hoffmann-La Roche, Inc. | KONOPKA, CATHERINE ANNE | §102§103§112 | Non-Final OA | — | Pending | May 09, 2024 | |
| 18658154 | SYSTEM FOR DETECTING MICRO-NEUROMAS AND METHODS OF USE THEREOF | President and Fellows of Harvard College | SIPES, JOHN CURTIS | 2872 | Other | Non-Final OA | — | Pending | May 08, 2024 |
| 18708275 | FLUID TREATMENT SYSTEM AND RELATED METHODS | Lignosol Ip Limited | BUSHEY, CHARLES S | 1776 | §102§103§112 | Non-Final OA | — | Pending | May 08, 2024 |
| 18655854 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | Thomas Jefferson University | LEE, ANDREW P | 1691 | §102§103 | Non-Final OA | — | Pending | May 06, 2024 |
| 18653106 | METHODS OF TREATING CANCER | Inspirna, Inc. | HUTTER, GILLIAN A | 1625 | §103DP | Non-Final OA | — | Pending | May 02, 2024 |
| 18706302 | DETECTION, STAGING, MONITORING AND TREATING A DISEASE OR A CONDITION | Sunbird Bio, Inc. | BOWERS, ERIN M | 1653 | §102Other | Non-Final OA | 20d | Pending | Apr 30, 2024 |
| 18647374 | SIGMA LIGAND COMPOUNDS AND USES THEREOF | Minerva Neurosciences, Inc. | RICCI, CRAIG D | §112 | Non-Final OA | — | Pending | Apr 26, 2024 | |
| 18645535 | FUNCTIONAL EEG MONTAGE FOR COGNITIVE SKILL DEVELOPMENT | Thynk, Inc. | JANG, CHRISTIAN Y | §103§112 | Non-Final OA | — | Pending | Apr 25, 2024 | |
| 18646092 | ENGINEERED TISSUE CONSTRUCTS AND USES THEREOF | Satellite Biosciences, Inc. | PELLEGRINO, BRIAN E | §102§103§112Other | Non-Final OA | — | Pending | Apr 25, 2024 | |
| 18704122 | CULTURE MEDIA AND CONDITIONS FOR IN VITRO EXPANSION AND/OR MATURATION OF HEPATOCYTES | Satellite Biosciences, Inc. | GU, QINHUA | 1633 | §102§103§112Other | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18634289 | CRYSTALLINE FORMS OF RAS INHIBITORS, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USE THEREOF | Revolution Medicines, Inc. | INAM, SAHAR | 1622 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18634241 | GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR THE TREATMENT OF ENDOMETRIOSIS | Kissei Pharmaceutical Co., Ltd. | HUI, SAN MING R | §103DP | Non-Final OA | — | Pending | Apr 12, 2024 | |
| 18698176 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING INFLAMMATORY LUNG DISEASES | DSM Nutritional Products, LLC | LAU, JONATHAN S | §102§103§112DP | Non-Final OA | — | Pending | Apr 03, 2024 | |
| 18693722 | PLATFORMS FOR DRUG TESTS AGAINST SYNUCLEINOPATHY USING HUMAN BRAIN ORGANOIDS | Okinawa Institute Of Science And Technology School Corporation | ROGERS, ERIC JASON | 1638 | §102§103§112 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18605744 | ASSAYS FOR ALPHA-DYSTROGLYCAN GLYCOSYLATION AND METHODS FOR USING SAME | Bridgebio Services Inc. | MONTGOMERY, ANN Y | §101§103§112 | Non-Final OA | — | Pending | Mar 14, 2024 | |
| 18691764 | SORBENTS AND METHODS FOR CARBON CAPTURE VIA CALCIUM LOOPING | UTI LIMITED PARTNERSHIP | HAILEY, PATRICIA L | §102§112 | Non-Final OA | — | Pending | Mar 13, 2024 | |
| 18691738 | SYNERGISTIC NANOMEDICINE DELIVERING TOPOISOMERASE I TOXIN (SN-38) AND INHIBITORS OF POLYNUCLEOTIDE KINASE 3'-PHOSPHATASE (PNKP) FOR ENHANCED TREATMENT OF COLORECTAL CANCER | The Governors of the University of Alberta | PROSSER, ALISSA J | 1619 | §103§112 | Non-Final OA | 53d | Pending | Mar 13, 2024 |
| 18602622 | GENE THERAPY FOR TUBEROUS SCLEROSIS | The General Hospital Corporation | VIVLEMORE, TRACY ANN | §102§112DP | Non-Final OA | — | Pending | Mar 12, 2024 | |
| 18690028 | PROCESS FOR FORMULATING COMPOSITIONS COMPRISING GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | Zealand Pharma A/S | REYNOLDS, FRED H | §102§103§112DP | Non-Final OA | — | Pending | Mar 07, 2024 | |
| 18688518 | METHODS FOR IDENTIFYING CROSS-MODAL FEATURES FROM SPATIALLY RESOLVED DATA SETS | The General Hospital Corporation | RIVERA-MARTINEZ, GUILLERMO M | 2677 | §112 | Final Rejection | 22d overdue | Pending | Mar 01, 2024 |
| 18688617 | METHODS OF PRODUCING HUMAN MILK OLIGOSACCHARIDES AND COMPOSITIONS THEREOF | Amyris, Inc. | MOEHLMAN, ANDREW TERRY | 1655 | §103§112 | Non-Final OA | — | Pending | Mar 01, 2024 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial67.8% of resolved applications prosecuted by Clark & Elbing LLP were allowed, across 8,993 applications in USPTO records.
3.89 office actions per allowed application on average.
167 pending office actions as of October 2026, for 98 clients, before 143 examiners in 64 art units.